PepGen Inc. (PEPG)
NMS · Healthcare · Biotechnology
$2.53
-2.69%
Closing price as of 2026-10-28 · Source: TEK2day Finance
Key Metrics
Market Cap
$175.0M
Shares Outstanding
69.2M
Exchange
NMS
Currency
USD
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (18.7M) | (19.7M) | (18.9M) | (18.9M) |
| Net Income | (18.0M) | (18.3M) | (17.8M) | (17.8M) |
| Diluted EPS | $-0.52 | $-0.27 | $-0.26 | $-0.26 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (68.3M) | (84.8M) | (97.7M) | (93.6M) |
| Net Income | (69.1M) | (78.6M) | (90.0M) | (89.7M) |
| Diluted EPS | $-2.91 | $-3.30 | $-2.85 | $-2.12 |